Cargando…
Cardiac α(V)β(3) integrin expression following acute myocardial infarction in humans
OBJECTIVE: Maladaptive repair contributes towards the development of heart failure following myocardial infarction (MI). The α(v)β(3) integrin receptor is a key mediator and determinant of cardiac repair. We aimed to establish whether α(v)β(3) integrin expression determines myocardial recovery follo...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566089/ https://www.ncbi.nlm.nih.gov/pubmed/27927700 http://dx.doi.org/10.1136/heartjnl-2016-310115 |
Sumario: | OBJECTIVE: Maladaptive repair contributes towards the development of heart failure following myocardial infarction (MI). The α(v)β(3) integrin receptor is a key mediator and determinant of cardiac repair. We aimed to establish whether α(v)β(3) integrin expression determines myocardial recovery following MI. METHODS: (18)F-Fluciclatide (a novel α(v)β(3)-selective radiotracer) positron emission tomography (PET) and CT imaging and gadolinium-enhanced MRI (CMR) were performed in 21 patients 2 weeks after ST-segment elevation MI (anterior, n=16; lateral, n=4; inferior, n=1). CMR was repeated 9 months after MI. 7 stable patients with chronic total occlusion (CTO) of a major coronary vessel and nine healthy volunteers underwent a single PET/CT and CMR. RESULTS: (18)F-Fluciclatide uptake was increased at sites of acute infarction compared with remote myocardium (tissue-to-background ratio (TBR(mean)) 1.34±0.22 vs 0.85±0.17; p<0.001) and myocardium of healthy volunteers (TBR(mean) 1.34±0.22 vs 0.70±0.03; p<0.001). There was no (18)F-fluciclatide uptake at sites of established prior infarction in patients with CTO, with activity similar to the myocardium of healthy volunteers (TBR(mean) 0.71±0.06 vs 0.70±0.03, p=0.83). (18)F-Fluciclatide uptake occurred at sites of regional wall hypokinesia (wall motion index≥1 vs 0; TBR(mean) 0.93±0.31 vs 0.80±0.26 respectively, p<0.001) and subendocardial infarction. Importantly, although there was no correlation with infarct size (r=0.03, p=0.90) or inflammation (C reactive protein, r=−0.20, p=0.38), (18)F-fluciclatide uptake was increased in segments displaying functional recovery (TBR(mean) 0.95±0.33 vs 0.81±0.27, p=0.002) and associated with increase in probability of regional recovery. CONCLUSION: (18)F-Fluciclatide uptake is increased at sites of recent MI acting as a biomarker of cardiac repair and predicting regions of recovery. TRIAL REGISTRATION NUMBER: NCT01813045; Post-results. |
---|